Home About Us Press releases CDMO Business Expansion

CDMO Business Expansion

mammalian cell culture

2017-11-06

FUJIFILM Corporation (President: Kenji Sukeno) is to invest a total of 3.2billion yen on its CDMO* sites in the U.S.A. and the U.K. in order to accelerate the expansion of the company’s business for developing and manufacturing biopharmaceuticals** under contract for other parties.

In addition to investing approximately 2.2 billion yen in a GMP facility dedicated to the production of monoclonal antibodies at the FUJIFILM Diosynth Biotechnologies (FDB) site in College Station, Texas, U.S.A., the company is also investing approximately 1.0 billion yen at its Wilton Centre site in Redcar, U.K., to expand the floor area of the development site of production processes for antibodies and install an additional facility. The new investment will expand the existing Saturn mAb™*** Process Development Laboratories dedicated to the development of monoclonal antibodies under FDB’s Platform. From Fall 2018 onwards, the new facilities will ramp up operation, bolstering the company’s ability to accept orders from its customers for process development and manufacturing in the field of antibodies.

Read more >